Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Argentina Lithium Exercises Property Options at Rincon West and Antofalla North (click to learn more) Heritage Mining - Drill Program Update and Planned Alcona Phase II Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Healthcare Biotechnology
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient... see more

Recent & Breaking News (TSX:FRX)

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 9, 2023

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 6, 2023

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

GlobeNewswire October 30, 2023

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire September 7, 2023

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 3, 2023

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

GlobeNewswire July 31, 2023

Fennec Announces Results of Annual Meeting

GlobeNewswire June 12, 2023

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi(TM) (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

GlobeNewswire June 6, 2023

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 11, 2023

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

GlobeNewswire May 8, 2023

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi(TM) (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

GlobeNewswire March 31, 2023

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

GlobeNewswire March 30, 2023

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

GlobeNewswire January 31, 2023

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

GlobeNewswire January 25, 2023

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 11, 2022

Fennec Pharma (TSX:FRX) PEDMARK is commercially available in the United States

Brieanna McCutcheon  October 17, 2022

Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States

GlobeNewswire October 17, 2022

Fennec Pharmaceuticals (TSX:FRX) closes second investment of $20M from Petrichor

John Ballem  September 26, 2022

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

GlobeNewswire September 26, 2022

Fennec Pharmaceuticals (TSX:FRX) receives FDA approval for PEDMARK (Sodium Thiosulfate Injection)

Brieanna McCutcheon  September 21, 2022